Home»Exposition»FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor

FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor

0
Shares
Pinterest Google+
FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor

SILVER SPRING, Md., Nov. 26, 2018 /PRNewswire/ — The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker). This is the second time the…

Previous post

Why are we destroying our own planet?

Next post

Pulse Electronics Releases PA4339.XXXNLT Small Form Factor Common Mode Choke